RCM
ZNTL icon

Regency Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Regency Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69K Hold
29,500
– – 0.03% 60
2025
Q4 		$39.8K Hold
29,500
– – 0.02% 62
2025
Q3 		$44.5K Hold
29,500
– – 0.02% 58
2025
Q2 		$34.2K Hold
29,500
– – 0.02% 58
2025
Q1 		$46.9K Hold
29,500
– – 0.03% 43
2024
Q4 		$89.4K Hold
29,500
– – 0.05% 49
2024
Q3 		$109K Hold
29,500
– – 0.06% 46
2024
Q2 		$121K Hold
29,500
– – 0.08% 47
2024
Q1 		$465K Sell
29,500
-300
-1% -$4.13K 0.3% 41
2023
Q4 		$451K Buy
29,800
+14,800
+99% +$216K 0.3% 42
2023
Q3 		$301K Buy
+15,000
New +$381K 0.26% 39

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Regency Capital Management's ZNTL Position: Q1 2026 in Review

Regency Capital Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 29,500 shares worth $69K. The position accounts for 0.03% of the portfolio, ranked #60.

Regency Capital Management first reported a position in ZNTL in Q3 2023 and has held it in 11 quarters since. The position peaked at $465K in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Regency Capital Management held 29,500 shares of Zentalis Pharmaceuticals worth $69K as of Q1 2026.
  • Regency Capital Management left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
  • Zentalis Pharmaceuticals made up 0.03% of Regency Capital Management's portfolio in Q1 2026, its #60 holding.
  • Regency Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Regency Capital Management's Zentalis Pharmaceuticals position peaked at $465K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Regency Capital Management's 13F filing for Q1 2026, filed 5 May 2026.